Physician profile

Keith Bloom

Urology · Irving, TX

NPI 1831177948

$7,761.68

in general payments reported to CMS, 2019-2025

43 companies · $1,134 in 2025

The $1,134 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,070.10
Grant$113.64

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $1,219.67 2019-2025 Myrbetriq, Xtandi, Veozah
Boston Scientific Corporation $925.29 2019-2025 Spaceoar Vue System - 10ml, Lithovue, Rezum Generator
Janssen Biotech, INC. $649.57 2019-2025 Erleada, Akeega
Abbvie INC. $505.55 2019-2024 Lupron Depot
Sumitomo Pharma America, INC. $488.43 2023-2025 Orgovyx, Gemtesa
Blue Earth Diagnostics $283.27 2019-2025 Posluma
Dendreon Pharmaceuticals LLC $273.95 2019-2024 Provenge
Pfizer INC. $268.47 2019-2025
Olympus America INC. $221.04 2024-2025 Itind System
Ferring Pharmaceuticals INC. $218.24 2019-2025 Adstiladrin
Axonics, INC. $218.02 2022-2024 Bulkamid, Axonics
Antares Pharma, INC. $215.28 2020-2025 Xyosted
Myovant Sciences INC. $211.77 2021-2022
Neotract INC. $188.26 2019-2020
Bayer Healthcare Pharmaceuticals INC. $186.12 2022-2025
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Procept Biorobotics Corporation $178.00 2024-2025 Aquabeam System
Palette Life Sciences, INC. $176.59 2022
Bioprotect Medical, INC. $167.78 2025 Bioprotect Balloon Implant System
Urogen Pharma, INC. $164.39 2020-2025 Jelmyto
Merck Sharp & Dohme LLC $161.42 2021-2024 Lynparza, Welireg, Keytruda
Accord Healthcare, INC. $112.57 2022-2025
Tolmar Pharmaceuticals, INC. $73.50 2020-2022
Laborie Medical Technologies Corp. $61.52 2022-2025
Travere Therapeutics, INC. $59.39 2019-2021
Myriad Genetic Laboratories, INC. $58.94 2021-2025 Myrisk, Prolaris
Healthtronics Stone Solutions, LLC $45.04 2022
Teleflex LLC $44.42 2021-2022
Tolmar, INC. $43.82 2025 Eligard, Jatenzo
Urovant Sciences INC $36.43 2022
Coloplast Corp $36.09 2021-2022
Valencia Technologies Corporation $36.01 2025 Ecoin Device Kit
Mission Pharmacal Company $35.76 2019-2024 Uribel Tabs
Novartis Pharmaceuticals Corporation $32.05 2025
Progenics Pharmaceuticals, INC. $23.70 2023 Pylarify
Endo USA, INC. $20.15 2024 Xiaflex
Cook Medical LLC $18.82 2024 Resonance
Janssen Pharmaceuticals, INC $17.13 2019
Medtronic, INC. $16.15 2024 Interstim
Kowa Pharmaceuticals America, INC. $15.60 2023 Seglentis
Azurity Pharmaceuticals, INC. $14.96 2025 Azmiro
Innocoll Pharmaceuticals Limited $14.40 2022
Telix Pharmaceuticals $13.14 2024 Illuccix
180 Medical, INC. $10.98 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Keith Bloom

$7,761.68

in general payments reported 2019-2025

Years
2019-2025
Top company
Astellas Pharma US INC
Context
The $1,134 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).

https://glasscript.com/doctor/264654/keith-bloom

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.